ZHONG JI LS (00767) plans to establish a joint venture with Bright Eyes to build the world's first AI + vision health ecosystem platform.

ZHONG JI LS (00767) announced that on April 13, 2026, its wholly-owned subsidiary Shenzhen Zhongji Health Science Co., Ltd. (Zhongji Health) signed a joint venture agreement with Guangdong Bright Eyes Technology Co., Ltd. (Bright Eyes) to establish a joint venture company in the People's Republic of China. At the time of establishment, Zhongji Health will own 51% and Bright Eyes will own 49% of the equity in the joint venture company. The joint venture company will mainly provide AI vision health and longevity health products and services globally, and build the world's first AI+ vision health ecological platform. The initial registered capital of the joint venture company is RMB 1 million, which will be contributed by Zhongji Health and Bright Eyes in proportion to their respective interests in the joint venture company. The funds will primarily be used for the operation of the joint venture company. The Group will provide funding through its internal resources and when completing the registration process with the Administration for Industry and Commerce of China. The announcement stated that the establishment of the joint venture company aligns with the Group's longevity science business development strategy and plan, and will benefit the future business development of the Group. The joint venture company is committed to building the world's first AI+ vision health ecological platform, focusing on the research and development, production, and global marketing of AI technology eye protection products. With products such as the world's only AI vision correction glasses, IPS exosome eye drops, and lutein series as the foundation, the company aims to create a complete AI vision health ecosystem and become a benchmark brand in the global technology eye protection field. The board of directors believes that the joint venture agreement will further enhance the Group's layout in the field of longevity science and explore new sources of income in longevity science for the company, bringing more stable and sustained income growth to the Group in the long run.